Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 3 2Phase 1 1

Status

Completed 3Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Head & Neck 1CNS 1

Conditions

Colorectal Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Glioma 1Glioblastoma 1Carcinoma 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Interventional × futuximab × Clear all
NCT03549338 2020-09-28

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

Symphogen A/S

Phase 2 Terminated
2 enrolled 9 charts
Gastrointestinal

Carcinoma, Colorectal Neoplasms

NCT02540161 2020-08-05

Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma

Duke University

Phase 2 Completed
43 enrolled 14 charts
CNS

Glioblastoma, Glioma

NCT02083653 2019-04-16

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

Symphogen A/S

Phase 2 Completed
254 enrolled 21 charts
Gastrointestinal

Colorectal Neoplasms

NCT01417936 2018-10-15

Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy

Symphogen A/S

Phase 2 Completed
26 enrolled 20 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02965417 2017-02-01

Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients

Symphogen A/S

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡